Eikon Therapeutics, Inc. EIKN
Set alert
At close
Pre-market · Nov 2, 4:00 AM ET
- YTD
- -64.60%
- 1 year
- -64.60%
- Open
- 5.27
- Prev close
- 5.35
- Mkt cap
- 287.62M
- Vol
- 553.13K
- Avg vol
- 561.63K
- EPS
- -8.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.01
- High
- 5.40
News
-
1 week ago benzinga.com
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting
EIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in…
1 week ago globenewswire.com
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to…
-
1 week ago benzinga.com
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…
-
2 weeks ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23
HC Wainwright & Co. analyst Sara Nik initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Buy rating and announces Price Target of $23.
-
2 weeks ago benzinga.com
Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer
Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced…